Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting - HARMONY Study
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Acronyms Harmony
- Sponsors AbbVie
- 27 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 15 Aug 2017 Planned number of patients changed from 350 to 200.
- 15 Aug 2017 Planned End Date changed from 5 Jul 2019 to 31 Dec 2018.